Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 19, 2004. The report details a share buyback transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests related to the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data presented relates to the share repurchase transaction:
- Shares Purchased: 950,000 Ordinary shares of 25 pence each.
- Purchase Date: August 17, 2004.
- Purchase Price: 1,063.13 pence per share.
- Treasury Holdings Post-Transaction: 35,618,000 shares.
- Shares in Issue (excluding Treasury): 5,898,448,643 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 950,000 shares for Treasury. Additionally, the GlaxoSmithKline Employee Trust transferred 2,570 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on August 18, 2004.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 950,000 share repurchase against the stated price of 1,063.13 pence per share.
- Confirm the updated total share capital and Treasury share count in subsequent filings.
- Review the impact of the 2,570 share transfer from the GSK Trust on the Employee Share Option Plan 1991.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.